ArticleJAAD case reports2024
Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: A case series and review of the literature.
Article in JAAD case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Real-world pharmacovigilance signals of antibody-drug conjugates: reporting patterns by payload, linker, target, and sex in FAERS.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- SJS/TEN following therapy with pembrolizumab and enfortumab vedotin in a patient with urothelial carcinoma.JAAD case reports · 2026Article
- Early-onset fatal toxic epidermal necrolysis after first-cycle enfortumab vedotin in an elderly patient with metastatic urothelial carcinoma.Urology case reports · 2026Article
- Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA Database.medRxiv : the preprint server for health sciences · 2025Article
- Enfortumab vedotin therapy complicated by bullous dermatitis: A case report.JAAD case reports · 2025Article
- Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding.IJU case reports · 2025Article
- Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.JAAD case reports · 2025Article
- Two rashes, one patient: Enfortumab vedotin-induced interface dermatitis and pembrolizumab-induced psoriatic disease treated with ixekizumab.JAAD case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.